172 related articles for article (PubMed ID: 31229298)
1. Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients.
Fuh KC; Java JJ; Chan JK; Kapp DS; Monk BJ; Burger RA; Young RC; Alberts DS; McGuire WP; Markman M; Bell J; Ozols RF; Armstrong DK; Aghajanian C; Bookman MA; Mannel RS
Gynecol Oncol; 2019 Aug; 154(2):420-425. PubMed ID: 31229298
[TBL] [Abstract][Full Text] [Related]
2. Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States.
Fuh KC; Shin JY; Kapp DS; Brooks RA; Ueda S; Urban RR; Chen LM; Chan JK
Gynecol Oncol; 2015 Mar; 136(3):491-7. PubMed ID: 25455734
[TBL] [Abstract][Full Text] [Related]
3. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group.
Albain KS; Unger JM; Crowley JJ; Coltman CA; Hershman DL
J Natl Cancer Inst; 2009 Jul; 101(14):984-92. PubMed ID: 19584328
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
duPont NC; Enserro D; Brady MF; Moxley K; Walker JL; Cosgrove C; Bixel K; Tewari KS; Thaker P; Wahner Hendrickson AE; Rubin S; Fujiwara K; Casey AC; Soper J; Burger RA; Monk BJ
Gynecol Oncol; 2022 Feb; 164(2):398-405. PubMed ID: 34857397
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
Oliver KE; Brady WE; Birrer M; Gershenson DM; Fleming G; Copeland LJ; Tewari K; Argenta PA; Mannel RS; Secord AA; Stephan JM; Mutch DG; Stehman FB; Muggia FM; Rose PG; Armstrong DK; Bookman MA; Burger RA; Farley JH
Gynecol Oncol; 2017 Nov; 147(2):243-249. PubMed ID: 28807367
[TBL] [Abstract][Full Text] [Related]
6. Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.
Garcia-Soto AE; Java JJ; Nieves Neira W; Pearson JM; Cohn DE; Lele SB; Tewari KS; Walker JL; Alvarez Secord A; Armstrong DK; Copeland LJ
Gynecol Oncol; 2016 Dec; 143(3):484-489. PubMed ID: 27726923
[TBL] [Abstract][Full Text] [Related]
7. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
[TBL] [Abstract][Full Text] [Related]
8. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.
Ferriss JS; Java JJ; Bookman MA; Fleming GF; Monk BJ; Walker JL; Homesley HD; Fowler J; Greer BE; Boente MP; Burger RA
Gynecol Oncol; 2015 Oct; 139(1):17-22. PubMed ID: 26216729
[TBL] [Abstract][Full Text] [Related]
9. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.
Chan JK; Teoh D; Hu JM; Shin JY; Osann K; Kapp DS
Gynecol Oncol; 2008 Jun; 109(3):370-6. PubMed ID: 18395777
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study.
Hamilton CA; Miller A; Casablanca Y; Horowitz NS; Rungruang B; Krivak TC; Richard SD; Rodriguez N; Birrer MJ; Backes FJ; Geller MA; Quinn M; Goodheart MJ; Mutch DG; Kavanagh JJ; Maxwell GL; Bookman MA
Gynecol Oncol; 2018 Feb; 148(2):275-280. PubMed ID: 29195926
[TBL] [Abstract][Full Text] [Related]
11. Endometrial cancer in Asian and American Indian/Alaskan Native women: tumor characteristics, treatment and outcome compared to non-Hispanic white women.
Mahdi H; Schlick CJ; Kowk LL; Moslemi-Kebria M; Michener C
Gynecol Oncol; 2014 Feb; 132(2):443-9. PubMed ID: 24316310
[TBL] [Abstract][Full Text] [Related]
12. Histological Tumor Type is Associated with One-Year Cause-Specific Survival in Women with Stage III-IV Epithelial Ovarian Cancer: A Surveillance, Epidemiology, and End Results (SEER) Database Population Study, 2004-2014.
Wu SG; Li FY; Lei J; Hua L; He ZY; Zhou J
Med Sci Monit; 2020 Feb; 26():e920531. PubMed ID: 32008036
[TBL] [Abstract][Full Text] [Related]
13. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer.
Mackay HJ; Brady MF; Oza AM; Reuss A; Pujade-Lauraine E; Swart AM; Siddiqui N; Colombo N; Bookman MA; Pfisterer J; du Bois A;
Int J Gynecol Cancer; 2010 Aug; 20(6):945-52. PubMed ID: 20683400
[TBL] [Abstract][Full Text] [Related]
14. Mortality in South Asians and Caucasians after percutaneous coronary intervention in the United Kingdom: an observational cohort study of 279,256 patients from the BCIS (British Cardiovascular Intervention Society) National Database.
Jones DA; Gallagher S; Rathod KS; Redwood S; de Belder MA; Mathur A; Timmis AD; Ludman PF; Townend JN; Wragg A;
JACC Cardiovasc Interv; 2014 Apr; 7(4):362-71. PubMed ID: 24742942
[TBL] [Abstract][Full Text] [Related]
15. Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study.
Phippen NT; Secord AA; Wolf S; Samsa G; Davidson B; Abernethy AP; Cella D; Havrilesky LJ; Burger RA; Monk BJ; Leath CA
Gynecol Oncol; 2017 Oct; 147(1):98-103. PubMed ID: 28743369
[TBL] [Abstract][Full Text] [Related]
16. Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218.
Wade KNS; Brady MF; Thai T; Wang Y; Zheng B; Salani R; Tewari KS; Gray HJ; Bakkum-Gamez JN; Burger RA; Moore KN; Bookman MA
Gynecol Oncol; 2019 Oct; 155(1):69-74. PubMed ID: 31409486
[TBL] [Abstract][Full Text] [Related]
17. Association of lymphadenectomy and survival in stage I ovarian cancer patients.
Chan JK; Munro EG; Cheung MK; Husain A; Teng NN; Berek JS; Osann K
Obstet Gynecol; 2007 Jan; 109(1):12-9. PubMed ID: 17197582
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study.
Tewari D; Java JJ; Salani R; Armstrong DK; Markman M; Herzog T; Monk BJ; Chan JK
J Clin Oncol; 2015 May; 33(13):1460-6. PubMed ID: 25800756
[TBL] [Abstract][Full Text] [Related]
19. Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
Manning-Geist BL; Chi DS; Long Roche K; Zivanovic O; Sonoda Y; Gardner GJ; O'Cearbhaill RE; Abu-Rustum NR; Leitao MM
Gynecol Oncol; 2021 Aug; 162(2):345-352. PubMed ID: 34045053
[TBL] [Abstract][Full Text] [Related]
20. Improved survival of Asians with corpus cancer compared with whites: an analysis of underlying factors.
Zhang MM; Cheung MK; Osann K; Lee MM; Gomez SS; Whittemore AS; Husain A; Teng NN; Chan JK
Obstet Gynecol; 2006 Feb; 107(2 Pt 1):329-35. PubMed ID: 16449120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
